Dr. Daver on the Utility of Maintenance Therapy in AML

preview_player
Показать описание
Naval G. Daver, MD, discusses the utility of maintenance chemotherapy in acute myeloid leukemia.

  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Dr. Daver on 0:02:15

Dr. Daver on the Utility of Maintenance Therapy in AML

Dr Daver on 0:01:53

Dr Daver on the Potential Utility of Uproleselan in R/R AML

Dr. Daver on 0:01:22

Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

Dr. Daver on 0:01:19

Dr. Daver on the Advancing Treatment Landscape in AML

Dr. Daver on 0:01:49

Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML

MDS/AML Overlap and 0:09:29

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

Checkpoint inhibitor advances 0:06:44

Checkpoint inhibitor advances in AML

Dr. Daver on 0:18:13

Dr. Daver on Stem Cell Transplant Considerations in Hematologic Malignancies in Light of COVID-19

Naval Daver on 0:02:17

Naval Daver on SOHO Italy 2020

Cool Tools of 0:07:08

Cool Tools of Doom: 1:26

Emerging therapies in 0:02:04

Emerging therapies in AML: why patients should be optimistic

Naval Daver, ASH 0:08:13

Naval Daver, ASH 2019: Venetoclax in Combination with Idasanutlin in Relapsed or Refractory AML

Dr. Komrokji on 0:01:51

Dr. Komrokji on the Current Treatment Landscape in MDS

Are Robots a 0:23:06

Are Robots a Threat to Humans? I Fortune

Sanam Loghavi MD 0:56:30

Sanam Loghavi MD - Virtual Pathology Grand Rounds - April 9, 2020

HMA in combination 0:01:12

HMA in combination with venetoclax and magrolimab in the treatment of AML

Exploring the Data 0:01:36

Exploring the Data for AML Treated With Magrolimab and Azacitidine

Are hypomethylating agents 0:01:56

Are hypomethylating agents useful in preventing relapse in AML and MDS?

MRD Evaluation in 0:23:13

MRD Evaluation in Hematological Neoplasm

Hypomethylating Agents for 0:03:40

Hypomethylating Agents for AML

Innovations in MDS 0:01:36

Innovations in MDS and AML treatment

BCL-2 Inhibitors With 0:04:10

BCL-2 Inhibitors With Hypomethylating Agents in AML

Debate: Hypomethylating agents 0:20:13

Debate: Hypomethylating agents are appropriate in lower-risk MDS - Only Use With Caution

Dr. DiNardo on 0:00:41

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML